FDA grants accelerated approval to Enhertu for metastatic HER2-positive cancers

[cafead]

via The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Enhertu for the treatment of adult patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment and lack satisfactory alternative options.

article source